ICU Medical (ICUI) to Release Quarterly Earnings on Thursday

ICU Medical (NASDAQ:ICUI) is expected to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of $1.44 per share and revenue of $543.33 million for the quarter.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, topping the consensus estimate of $1.23 by $0.49. ICU Medical had a positive return on equity of 6.75% and a negative net margin of 3.87%. The business had revenue of $599.49 million for the quarter, compared to analyst estimates of $574.15 million. During the same quarter in the previous year, the company earned $0.96 EPS. The company’s quarterly revenue was up 6.7% on a year-over-year basis. On average, analysts expect ICU Medical to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

ICU Medical Stock Performance

NASDAQ ICUI opened at $125.47 on Thursday. The business has a 50 day moving average price of $130.70 and a 200 day moving average price of $142.18. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.59 and a quick ratio of 1.52. The company has a market capitalization of $3.09 billion, a P/E ratio of -32.76 and a beta of 0.87. ICU Medical has a 1-year low of $117.92 and a 1-year high of $196.26.

Insider Activity

In other ICU Medical news, Director David C. Greenberg sold 1,942 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $143.66, for a total transaction of $278,987.72. Following the transaction, the director owned 6,760 shares of the company’s stock, valued at $971,141.60. This represents a 22.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Ben Sousa sold 2,000 shares of ICU Medical stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $137.36, for a total value of $274,720.00. Following the completion of the sale, the insider directly owned 479 shares of the company’s stock, valued at approximately $65,795.44. This represents a 80.68% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 36,097 shares of company stock worth $4,860,156. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Large investors have recently bought and sold shares of the stock. United Services Automobile Association purchased a new stake in shares of ICU Medical during the 1st quarter worth about $218,000. AQR Capital Management LLC lifted its position in ICU Medical by 2.5% during the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock valued at $1,297,000 after buying an additional 229 shares in the last quarter. Intech Investment Management LLC lifted its position in ICU Medical by 38.6% during the first quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock valued at $1,658,000 after buying an additional 3,326 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in ICU Medical by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock worth $1,772,000 after buying an additional 560 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of ICU Medical by 32.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock worth $9,472,000 after acquiring an additional 16,680 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Wall Street Analyst Weigh In

ICUI has been the subject of several research reports. Raymond James Financial cut their price target on ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating for the company in a research note on Friday, May 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a report on Tuesday, April 8th. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday, May 18th. Finally, KeyCorp reduced their target price on ICU Medical from $209.00 to $191.00 and set an “overweight” rating on the stock in a research note on Monday, April 21st. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $192.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.